These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

365 related articles for article (PubMed ID: 24571382)

  • 1. The role of homocysteine-lowering B-vitamins in the primary prevention of cardiovascular disease.
    Debreceni B; Debreceni L
    Cardiovasc Ther; 2014 Jun; 32(3):130-8. PubMed ID: 24571382
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Why do homocysteine-lowering B vitamin and antioxidant E vitamin supplementations appear to be ineffective in the prevention of cardiovascular diseases?
    Debreceni B; Debreceni L
    Cardiovasc Ther; 2012 Aug; 30(4):227-33. PubMed ID: 21884001
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Homocysteine and cardiovascular disease: a review of the evidence.
    Wierzbicki AS
    Diab Vasc Dis Res; 2007 Jun; 4(2):143-50. PubMed ID: 17654449
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The controversial role of B-vitamins in cardiovascular risk: An update.
    Ntaios G; Savopoulos C; Grekas D; Hatzitolios A
    Arch Cardiovasc Dis; 2009 Dec; 102(12):847-54. PubMed ID: 19963194
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The homocysteine hypothesis: still relevant to the prevention and treatment of cardiovascular disease?
    Abraham JM; Cho L
    Cleve Clin J Med; 2010 Dec; 77(12):911-8. PubMed ID: 21147945
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Updating the relationship between hyperhomocysteinemia lowering therapy and cardiovascular events.
    Cheng X
    Cardiovasc Ther; 2013 Aug; 31(4):e19-26. PubMed ID: 23082962
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Vitamin treatments that lower homocysteine concentration: can they decrease cerebrovascular disease in primary prevention?].
    Méndez-González J; Rodríguez-Millán E; Julve J; Blanco-Vaca F
    Rev Neurol; 2010 Feb 16-28; 50(4):235-44. PubMed ID: 20198596
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical use and rational management of homocysteine, folic acid, and B vitamins in cardiovascular and thrombotic diseases.
    Stanger O; Herrmann W; Pietrzik K; Fowler B; Geisel J; Dierkes J; Weger M
    Z Kardiol; 2004 Jun; 93(6):439-53. PubMed ID: 15252738
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Homocysteine-lowering trials for prevention of heart disease and stroke.
    Clarke R
    Semin Vasc Med; 2005 May; 5(2):215-22. PubMed ID: 16047274
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Homocysteine, B-vitamins and CVD.
    McNulty H; Pentieva K; Hoey L; Ward M
    Proc Nutr Soc; 2008 May; 67(2):232-7. PubMed ID: 18412997
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Group B vitamins as new variables related to the cardiovascular risk].
    Granieri M; Bellisarii FI; De Caterina R
    Ital Heart J Suppl; 2005 Jan; 6(1):1-16. PubMed ID: 15776726
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Homocysteine lowering with folic acid and vitamin B supplements: effects on cardiovascular disease in older adults.
    Carlsson CM
    Drugs Aging; 2006; 23(6):491-502. PubMed ID: 16872232
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of B vitamins status and homocysteine levels in elderly Taiwanese.
    Chen KJ; Pan WH; Yang FL; Wei IL; Shaw NS; Lin BF
    Asia Pac J Clin Nutr; 2005; 14(3):250-5. PubMed ID: 16169836
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Disturbances of homocysteine metabolism as a risk factor of cardiovascular diseases development: effect on prognosis and possibilities of correction with drugs].
    Shakhmatova OO; Komarov AL; Panchenko EP
    Kardiologiia; 2010; 50(1):42-50. PubMed ID: 20144157
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vitamin supplements and cardiovascular risk: review of the randomized trials of homocysteine-lowering vitamin supplements.
    Clarke R; Armitage J
    Semin Thromb Hemost; 2000; 26(3):341-8. PubMed ID: 11011852
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Public health control of hyperhomocysteinemia and its consequences].
    Czeizel E; Kalina A
    Orv Hetil; 2003 Oct; 144(40):1981-9. PubMed ID: 14626640
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Homocysteine-lowering therapy does not affect inflammatory markers of atherosclerosis in patients with stable coronary artery disease.
    Bleie Ø; Semb AG; Grundt H; Nordrehaug JE; Vollset SE; Ueland PM; Nilsen DW; Bakken AM; Refsum H; Nygård OK
    J Intern Med; 2007 Aug; 262(2):244-53. PubMed ID: 17645592
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Homocysteine and coronary atherosclerosis: from folate fortification to the recent clinical trials.
    Antoniades C; Antonopoulos AS; Tousoulis D; Marinou K; Stefanadis C
    Eur Heart J; 2009 Jan; 30(1):6-15. PubMed ID: 19029125
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Controlled trials of very high dose folic acid, vitamins B12 and B6, intravenous folinic acid and serine for treatment of hyperhomocysteinemia in ESRD.
    Gonin JM; Nguyen H; Gonin R; Sarna A; Michels A; Masri-Imad F; Bommareddy G; Chassaing C; Wainer I; Loya A; Cary D; Barker LF; Assefi A; Greenspan R; Mahoney D; Wilcox CS
    J Nephrol; 2003; 16(4):522-34. PubMed ID: 14696754
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative study of response to treatment with supraphysiologic doses of B-vitamins in hyperhomocysteinemic hemodialysis patients.
    Nakhoul F; Abassi Z; Plawner M; Khankin E; Ramadan R; Lanir N; Brenner B; Green J
    Isr Med Assoc J; 2004 Apr; 6(4):213-7. PubMed ID: 15115259
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.